Literature DB >> 28943102

Hypothalamic pathways regulate the anorectic action of p-chloro-diphenyl diselenide in rats.

Cristiani F Bortolatto1, Cristina W Nogueira2, Begoña Porteiro3, Mónica Imbernón3, Ruben Nogueiras3.   

Abstract

Behavioral studies have suggested that (p-ClPhSe)2 elicits an anorectic-like action in rats by inducing multiple effects such as satiety-enhancing effect, malaise and specific flavor; however, the molecular mechanisms underlying its anorexigenic action remain unclarified. Here, male Sprague-Dawley rats received acute and sub-chronic intraperitoneal treatments with (p-ClPhSe)2; thereafter, in vivo and ex vivo analyses were carried out. The present study reveals that the reduction of food intake resulting from a single treatment with (p-ClPhSe)2 (1mg/kg, i.p.) was associated with decreased hypothalamic levels of pro-melanin-concentrating hormone (pro-MCH) and orexin precursor. In addition, repeated administrations of (p-ClPhSe)2 (10mg/kg; i.p.) for 7 days induced sustained food intake suppression, body weight loss and white fat reduction. Measurements of brown adipose tissue content and temperature as well as data obtained from a pair-fed group indicated that the effects of (p-ClPhSe)2 on the body weight are closely related to its anorexigenic actions, ruling out the possibility of increased thermogenesis. Furthermore, (p-ClPhSe)2 reduced the hypothalamic orexin precursor levels when repeatedly administered to rats. Sub-chronic treatment with (p-ClPhSe)2 caused a decrease of serum triglyceride levels and down-regulation of hepatic cholesterol content. Therefore, the current study characterized the anorectic and reducing body weight actions of (p-ClPhSe)2 in Sprague-Dawley rats. Besides, the set of results suggests that food intake suppressant effects triggered after (p-ClPhSe)2 administration to rats are mainly related with the lower orexin levels in hypothalamus after acute and sub-chronic treatments.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Appetite suppressant; Body weight loss; Neuropeptides; Orexin; Selenium

Mesh:

Substances:

Year:  2017        PMID: 28943102     DOI: 10.1016/j.ejphar.2017.09.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  The neurotherapeutic role of a selenium-functionalized quinoline in hypothalamic obese rats.

Authors:  Ethel Antunes Wilhelm; Cristiane Luchese; Karline C Rodrigues; Cristiani F Bortolatto; Ketlyn P da Motta; Renata L de Oliveira; Jaini J Paltian; Roberta Krüger; Silvane S Roman; Silvana P Boeira; Diego Alves
Journal:  Psychopharmacology (Berl)       Date:  2021-03-19       Impact factor: 4.530

Review 2.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

Review 3.  Selenium and Selenoproteins in Adipose Tissue Physiology and Obesity.

Authors:  Alexey A Tinkov; Olga P Ajsuvakova; Tommaso Filippini; Ji-Chang Zhou; Xin Gen Lei; Eugenia R Gatiatulina; Bernhard Michalke; Margarita G Skalnaya; Marco Vinceti; Michael Aschner; Anatoly V Skalny
Journal:  Biomolecules       Date:  2020-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.